n | Prevalence (95% CI) | |
Morbidity | ||
Cancer* | 87 386 | 34.7 (34.5 to 34.9) |
Heart disease† | 32 690 | 13.0 (12.9 to 13.1) |
Diabetes | 22 575 | 9.0 (8.9 to 9.1) |
Parkinson’s disease | 1566 | 0.6 (0.6 to 0.7) |
Stroke | 7893 | 3.1 (3.1 to 3.2) |
Depression or anxiety | 46 343 | 18.4 (18.3 to 18. 6) |
Asthma‡ | 31 316 | 12.4 (12.3 to 12.6) |
Allergic rhinitis‡ | 34 509 | 13.7 (13.6 to 13.9) |
Hypertension | 78 135 | 31.0 (30.9 to 31.2) |
Thrombosis | 13 834 | 5.5 (5.4 to 5.6) |
Musculoskeletal conditions§ | 29 986 | 11.9 (11.8 to 12.0) |
Multimorbidity (≥2 morbidities) | 111 084 | 44.1 (43.9 to 44.3) |
Body system morbidity: any conditions within these systems¶ | ||
Cardiovascular | 128 069 | 50.9 (50.7 to 51.1) |
Musculoskeletal | 35 272 | 14.0 (13.9 to 14.2) |
Neurological | 1566 | 0.6 (0.6 to 0.7) |
Psychological | 46 343 | 18.4 (18.3 to 18. 6) |
Respiratory | 55 279 | 22.0 (21.8 to 22.1) |
Skin | 13 811 | 5.5 (5.4 to 5.6) |
Endocrine/metabolic | 33 533 | 13.3 (13.2 to 13.5) |
F genital** | 7300 | 2.9 (2.8 to 3.0) |
M genital†† | 23 850 | 9.5 (9.4 to 9.6) |
Complex multimorbidity (≥3 body system) | 39 478 | 15.7 (15.5 to 15.8) |
*Cancer includes melanoma, breast cancer (F), prostate cancer (M) and other cancer.
†Heart disease includes heart attack, angina or other heart disease.
‡Asthma and allergic rhinitis were collected as aggregated for the first ~15% people, but they were separated for the remaining people.
§Musculoskeletal includes osteoarthritis, osteoporosis or low bone density.
¶Body system morbidities: cardiovascular includes heart disease, high blood pressure, blood clot (thrombosis), heart attack or angina and other heart disease; musculoskeletal includes osteoarthritis, osteoporosis or low bone density; neurological includes Parkinson’s disease; psychological includes depression or anxiety; respiratory includes asthma or allergic rhinitis; skin includes melanoma; endocrine/metabolic includes diabetes and thyroid problems; F genital includes breast cancer; M genital includes prostate cancer or enlarged prostate.
**Denominator for this estimate was the total number of F participants.
††Denominator for this estimate was the total number of M participants.
F, female; M, male.